

Suppl table 1. Other published works (ARMS: Amplification Refractory Mutation System; inh: inhibitors; mut: mutated; wt: wild type)

Author	Nº patients (Adv Stage)	BRAF	Stage	Treatment	Sample	Method	Analytical Sensitivity	Diagnostic Sensitivity
Shinozaki ²⁸	48 (29)	mut/wt	I-IV	Biochemo	serum	Real-time quantitative PCR+PNA clamp and FRET LNA probe	0.10%	39%
Board ³²	45	mut	IV	MEK1/2 i	serum	ARMS	0.01%	55.6%
Aung ³¹	221	mut/wt	IV	MEK1/2 i	serum/plasma	ARMS	2%	44-52%
Ascierto ²⁷	72	mut	IV	BRAF i	-	BEAMing	-	79%
Panka ²⁹	128 (27)		II-IV	18 BRAFi/MEK i	plasma	RT-PCR with TspR1 (restriction site)	0.001%	96%
Gonzalez Cao	22	mut	IV	BRAF i	serum/plasma	Taqman Assay+PNA clamp	0.005%	57.7%